Ambalal Sarabhai Enterprises Ltd

Consolidated results

• Board approved unaudited consolidated results for quarter ended 30 Jun 2026.
• Net sales from operations: Rs 4,356.26 lakhs; Total income: Rs 4,559.02 lakhs.
• Pharma revenue: Rs 2,526.10 lakhs; Electronics: Rs 1,832.68 lakhs; inter-segment: Rs (2.52) lakhs.
• Consolidated segment pre-tax results: Pharma 438.47; Electronics 127.16; total 565.63 lakhs.
• Interest & finance costs: Rs 97.77 lakhs; Profit from ordinary activities: Rs 467.86 lakhs.
• Net profit after tax: Rs 397.58 lakhs.
• One-time exceptional item under New Labour Codes: Rs 81.99 crores (net of tax) recognized in FY2026.
• Auditor's review: Consolidated results reviewed with unqualified opinion.
• Annexure I: Consolidated assets - Pharma 20,752.91; Electronics 6,317.52; Total 27,070.43.
• Annexure I: Consolidated liabilities - Pharma 4,706.13; Electronics 1,042.72; Total 5,748.85.

Notes on disclosures

• Board meeting held on 12 August 2026; results accompanied by Limited Review Report.
• Standalone results also reviewed; auditor: Sorab S. Engineer & Co.; unqualified opinion.

Price movement clarification

• Clarification that price movements are market-driven and no unpublished price-sensitive information exists.
• Company states it has promptly disclosed all material information under Regulation 30 and LODR.
• Will promptly inform the Stock Exchange of any material event as required.
• Affirms ongoing compliance with SEBI LODR requirements.
• Signed by Ms. Disha Punjani, Company Secretary & Compliance Officer.

Plant visit details

• Plant visit for shareholders rescheduled to 01 December 2026, 3:00–5:00 PM.
• Original date was 26 October 2026.
• Registration deadline set for 20 November 2026.
• Location: Sarabhai campus, Opp. Ranoli Railway Station, Ranoli, Gujarat.
• Participants to register with Folio No./DP ID and confirm by email or phone.
• Contact: dpunjani@ase.life or +91 9099013477.
• Company Secretary & Compliance Officer: Ms. Disha Punjani.

Meeting Details

• Date, time, and venue not disclosed in this filing chunk.

AGM details

• Date/time/mode: 30-07-2026, 11:00 AM to 11:58 AM, VC/OAVM.
• Record date: 23-07-2026; last date for postal ballots: 30-07-2026.
• Shareholders on record: 167,713; VC attendees: 55 (24 promoters, 31 public).

Key resolutions

• Resolution 1 (Ordinary): Adopt standalone and consolidated financial statements for 2025-26.
• Resolution 2 (Ordinary): Re-appoint Kartikeya V. Sarabhai as Director (retiring by rotation).
• Resolution 3 (Special): Re-appoint Kartikeya V. Sarabhai as Executive Chairman for 3 years.
• Resolution 4 (Special): Re-appoint Chaula M. Shastri as Whole-time Director for 3 years.
• Resolution 5 (Special): Re-appoint Mohal K. Sarabhai as Managing Director for 3 years.
• Resolution 6 (Special): Approve loans/investments/guarantee/security under section 185 for Synbiotics Ltd.
• Resolution 7 (Special): Approve loans/investments/guarantee/security under section 185 for Asence Pharma Pvt Ltd.
• Resolution 8 (Special): Approve loans/investments/guarantee/security under section 185 for Systronics India Ltd.
• Resolution 9 (Special): Continue Govindprasad Namdeo as Non-Executive Independent Director.

Voting results

• Resolution 1: Passed; 100% in favour.
• Resolution 2: Passed; 100% in favour.
• Resolution 3: Passed; overwhelming support with minor opposition.
• Resolution 4: Passed; overwhelming support with minor opposition.
• Resolution 5: Passed; overwhelming support with minor opposition.
• Resolution 6: Passed; 99.85% in favour, 0.15% against.
• Resolution 7: Passed; 99.85% in favour, 0.15% against.
• Resolution 8: Passed; 99.85% in favour, 0.15% against.
• Resolution 9: Passed; 99.95% in favour, 0.05% against.

Material related party transactions

• Synbiotics Limited: loans/investments/guarantee/security approved (value not disclosed).
• Asence Pharma Private Limited: loans/investments/guarantee/security approved (value not disclosed).
• Systronics India Limited: loans/investments/guarantee/security approved (value not disclosed).

Director changes

• Kartikeya V. Sarabhai: re-appointed as Director (retiring by rotation).
• Kartikeya V. Sarabhai: appointed as Executive Chairman for 3 years from 01-04-2027.
• Chaula M. Shastri: Whole-time Director for 3 years from 01-04-2027.
• Mohal K. Sarabhai: Managing Director for 3 years from 21-09-2026.
• Govindprasad Namdeo: continuation as Non-Executive Independent Director on turning 75.

agm details

• AGM held on 30 July 2026 via VC/OAVM, 11:00–12:00 IST.
• Chaired by Executive Chairman Kartikeya V. Sarabhai.
• Remote e-voting conducted 27–29 July 2026.

key resolutions

• Ordinary: Adoption of standalone and consolidated financial statements for 2025-26.
• Special: Re-appointment of Executive Chairman for 3 years from 1 Apr 2027.
• Special: Re-appointment of Whole-time Director for 3 years from 1 Apr 2027.
• Special: Re-appointment of Managing Director for 3 years from 21 Sep 2026.
• Special: Approvals of loans/investments/guarantees under section 185 for Synbiotics Limited.
• Special: Approvals of loans/investments/guarantees under section 185 for Asence Pharma Private Limited.
• Special: Approvals of loans/investments/guarantees under section 185 for Systronics India Limited.
• Special: Continuation of Non-Executive Independent Director upon attaining age 75.

voting results

• Adoption of financial statements: voting results not disclosed.
• Executive Chairman re-appointment: voting results not disclosed.
• Whole-time Director re-appointment: voting results not disclosed.
• Managing Director re-appointment: voting results not disclosed.
• Synbiotics Limited loans: voting results not disclosed.
• Asence Pharma Private Limited loans: voting results not disclosed.
• Systronics India Limited loans: voting results not disclosed.
• Continuation of Independent Director at 75: voting results not disclosed.

director changes

• Re-appointment of Executive Chairman for 3 years.
• Re-appointment of Whole-time Director for 3 years.
• Re-appointment of Managing Director for 3 years.
• Continuation of Non-Executive Independent Director upon attaining age 75.

related party transactions

• Loans/investments/guarantees approved for Synbiotics Limited.
• Loans/investments/guarantees approved for Asence Pharma Private Limited.
• Loans/investments/guarantees approved for Systronics India Limited.

Overview & financials

• Consolidated turnover (net): ₹202.27 Cr; total income ₹217.44 Cr.
• Consolidated net profit after tax: ₹17.80 Cr.
• EPS (Standalone) Basic/Diluted: ₹1.43 for FY26.
• Dividend not declared for the year.

Revenue & segments

• Pharmaceuticals segment revenue: ₹11,050.62 Lakh; Electronics: ₹9,177.64 Lakh.
• Geography: Domestic ₹13,679.49 Lakh; Rest of world ₹6,547.68 Lakh; Total ₹20,227.17 Lakh.
• Segment pre-finance profit: Pharma ₹1,315.20; Electronics ₹1,026.06; Total ₹2,341.26.

Capital structure & liquidity

• Total borrowings: ₹5,164.51 Lakh; cash & bank balances ₹1,940.77 Lakh.
• Net debt ₹3,223.74 Lakh; gearing 16.91%.
• Standalone equity ₹5,948.22 Lakh; equity share capital ₹7,663.33 Lakh.

AGM & governance actions

• AGM 48th on 30-07-2026 via VC/OAVM.
• Item 3: Re-appoint Executive Chairman for 3 years from 01-04-2027.
• Item 4: Re-appoint Chaula M. Shastri as Whole-time Director for 3 years from 01-04-2027.
• Item 5: Re-appoint Mohal K. Sarabhai as MD for 3 years from 21-09-2026.
• Item 6: Approve loans/guarantees to Synbiotics up to ₹10 Cr.
• Item 7: Approve loans/guarantees to Asence Pharma Pvt Ltd up to ₹10 Cr.
• Item 8: Approve loans/guarantees to Systronics India Ltd up to ₹10 Cr.
• Item 9: Continuation of Govindprasad Namdeo as Non-Executive Independent Director post-75.
• Remote e-voting: 27-29 July 2026; cut-off 23 July.

Subsidiaries, associates & joint ventures

• Board includes 8 subsidiaries, 2 joint ventures, and 1 associate.
• Material subsidiaries include Synbiotics Ltd, Systronics (India) Ltd, Asence Pharma Pvt Ltd, Sarabhai M Chemicals.

Related party disclosures & governance

• RPTs are arm's length and approved by Audit Committee.
• Key management personnel remuneration totaled ₹326.96 Lakh (FY24-25) and ₹324.82 Lakh (FY25-26).
• Loans & advances to related parties ₹700.35 Lakh (FY26) vs ₹622.33 Lakh (FY25).

Audit, controls & risk

• Statutory auditors: Sorab S. Engineers & Co.; Secretarial: RPSS & Co.; Internal auditor: Gautam Joshi & Co.
• Auditors’ reports are unqualified; BRR included; internal controls deemed adequate.

CSR & strategic developments

• CSR expenditure ₹18.14 Lakh in FY26; ₹15.50 Lakh prior year.
• Demerger of Oncology & Pro-Fertility division into Asence Pharma Pvt Ltd to sharpen focus.